Stories about Health / Medicine

Subscribe to topic

Subscribe to Health / Medicine

16.01.2019 – 11:00
Lipotype
Lipotype announces "Lipidomics Excellence Award" for Breakthrough Lipidomics Projects / Call for Applications open till 30 March, 2019
Dresden/Germany (ots) - The international scientific community is called to submit applications for the premiere of the world's first award for cutting edge contributions to the progress of life sciences through lipidomics, the 2019 "Lipidomics Excellence Award" (LEA) until 30 March, 2019. Prof. Dr. Kai Simons, ...
10.01.2019 – 11:10
nutriCARD
Cardiovascular diseases and nutrition in Europe: every second to third premature death preventable
03.01.2019 – 11:43
ATAI Life Sciences
ATAI Life Sciences acquires majority stake in Perception Neuroscience to develop arketamine therapy for neuropsychiatric diseases
Munich and New York (ots) - ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry. Perception was founded by Jonathan Sporn, MD, and Jay Kranzler, MD, PhD, both of whom have held ...
14.12.2018 – 08:00
Grünenthal Group
Joint Press Release: Grünenthal and OnDosis team up for individualised dosing of oral drugs in pain management to increase patient safety
Aachen, Germany and Gothenburg, Sweden (ots) - - Grünenthal expands its portfolio with an innovative technology for individualised dosing - Life science startup OnDosis signs its first global development and licensing agreement for their innovative technology Grünenthal and OnDosis announced today that they have ...
13.12.2018 – 16:06
OD-OS GmbH
APVRS 2018: Intuitive Iridotomy Treatment with the Navilas® 577s Retina Laser Released by OD-OS
11.12.2018 – 11:30
Lohmann & Rauscher
Dr. Klemens Schulz appointed CPO of the L&R Corporate Group
03.12.2018 – 09:56
Grünenthal Gruppe
Grünenthal closes deal with AstraZeneca for Nexium and Vimovo
Aachen, Germany (ots) - Grünenthal today announced the successful completion of its acquisition of European rights to Nexium and global (ex US and Japan) rights to Vimovo from AstraZeneca for a total consideration of up to US$ 922 m (EUR 811 m). "Today is an important day for Grünenthal," said Gabriel Baertschi, CEO Grünenthal. "This transaction represents a significant step towards our vision of creating a world free ...
19.11.2018 – 16:15
Nano-Care Deutschland AG
Invisible self-disinfection: "wipe-on glass" enables permanent hygiene and protection from infection through creation of antimicrobial surfaces
14.11.2018 – 13:00
Averitas Pharma
Averitas Pharma commercializes Qutenza® in the US
Morristown, New Jersey (ots) - Averitas Pharma, a recently acquired Grünenthal Group company, announced that it has taken over the US commercialization of Qutenza® (capsaicin) 8% patch on October 30, after the acquisition of the product by Grünenthal on the same day. Qutenza® is approved in the US for the management of neuropathic pain associated with postherpetic neuralgia. A single, 1-hour, localized treatment with ...
14.11.2018 – 08:45
Grünenthal Group
Grünenthal acquires Averitas Pharma and establishes commercial footprint in the US
Aachen, Germany / Morristown, New Jersey, USA (ots) - Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the ...
05.11.2018 – 12:10
Grünenthal Group
Grünenthal acquires global rights for Qutenza®
Aachen (ots) - Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza® (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grünenthal is now the sole owner of Qutenza® worldwide, including the US, Latin America, Asia and Australia. Grünenthal had already acquired exclusive commercial rights for ...
05.11.2018 – 12:00
Sysmex Inostics GmbH
Sysmex Inostics OncoBEAM(TM) circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers
Hamburg, Germany (ots) - Recent data published in Annals of Oncology (https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy417/5139593) from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA (ctDNA) may offer clinicians higher-resolution information ...
30.10.2018 – 08:43
Grünenthal Group
Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo
Aachen (ots) - - Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management - Gastroprotective therapies to address a high unmet medical need [1] in pain patients on non-steroidal anti-inflammatory drugs (NSAIDs) Grünenthal today announced that it has agreed to acquire AstraZeneca's European ...
23.10.2018 – 14:00
Debiopharm International SA
GenePOC® launches its GenePOC® CDiff test in Canada
Québec, Canada (ots) - GenePOC announces the Health Canada approval and launch of its molecular diagnostic test for the detection of Clostridium difficile in Canada GenePOC Inc., member of the Debiopharm Group, is proud to announce the approval by Health Canada and the launch of its GenePOC CDiff assay to be used with the revogene(TM) instrument. About the Clostridium difficile infection (CDI) In Canada, CDI is the main ...
18.10.2018 – 12:00
Sysmex Inostics GmbH
Sysmex Inostics' OncoBEAM(TM) platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers
Hamburg, Germany (ots) - Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups demonstrate the importance of a highly sensitive test for detection of clinically-relevant mutations present in circulating tumor DNA (ctDNA) derived ...
15.10.2018 – 13:06
Sysmex Inostics GmbH
Sysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...
12.10.2018 – 09:00
European Society for Medical Oncology (ESMO)
Breast cancer patients use Twitter as a non-medical forum to share their experiences
Lugano/Munich (ots) - Twitter is a place where many cancer patients share and discuss their experiences, a study at the ESMO 2018 Congress reveals, based on analysis of the contents of over 6,000 tweets and retweets about breast cancer. The study was part of a larger, multidisciplinary project to observe the presence of different diseases on social media. The data ...
11.10.2018 – 12:00
Debiopharm International SA
Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic product in Oncology
Lausanne, Villigen, Switzerland (ots) - Debiopharm International SA (Debiopharm), a Swiss-based biopharmaceutical company and the Paul Scherrer Institute (PSI), the largest research institute for natural and engineering sciences in Switzerland, today announced a collaboration to pursue the development of a ...
10.10.2018 – 07:10
PAUL HARTMANN AG
Britta Fuenfstueck appointed as new CEO of the HARTMANN GROUP
02.10.2018 – 14:30
Sysmex Europe GmbH
In vitro diagnostics company Sysmex Europe announces executive leadership change
Norderstedt (ots) - Sysmex Europe GmbH, which oversees Sysmex's operations in EMEA (Europe, Middle East & Africa), has announced its Chairman and long-time President & CEO Dr Jürgen Schulze decided in early 2018 to retire effective 30 September 2018, however will continue to benefit and support Sysmex as a member and vice-chairman of the MedTech Europe Executive ...
27.09.2018 – 11:00
Gerresheimer AG
Micro pump for Parkinson's treatment from Gerresheimer subsidiary Sensile Medical receives European CE declaration of conformity
Duesseldorf/Olten (ots) - A wearable micro pump from Sensile Medical has received EU certification for the European market. A European pharma company has obtained a CE declaration of conformity for the pump, which is specially designed for the ...
One document
25.09.2018 – 11:52
WSSCC
India hosts the Mahatma Gandhi International Sanitation Convention / 29th September to 2nd October 2018, New Delhi
New Delhi (ots) - Ministers and sanitation sector leaders from around the world will convene this month at the Mahatma Gandhi International Sanitation Convention (MGISC) in New Delhi. Hosted by the Government of India, this event will be an opportunity for delegates to exchange sanitation successes and best ...
19.09.2018 – 14:00
Jennewein Biotechnologie GmbH
Jennewein Biotechnologie develops new fermentation technology for human milk oligosaccharides and expands its product portfolio
Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH announces the introduction of a total biosynthesis approach for the production of human milk oligosaccharides (HMOs). Currently the production of HMOs by fermentation requires lactose as a starting material. Lactose is a costly dairy by-product and is difficult to ...
17.09.2018 – 16:00
Fresenius Kabi
Fresenius Kabi to Announce Winner of EUR 100,000* Research Grant to Support Parenteral Nutrition Research in Latin America at the FELANPE Congress in Mexico
Bad Homburg (ots) - Global healthcare company Fresenius Kabi will announce the winner of the first EUR 100,000* Parenteral Nutrition Research Grant Latin America at the FELANPE congress in Guadalajara, Mexico, from September 22-25. The announcement will be made during Fresenius Kabi's satellite symposium, in Salón ...
28.08.2018 – 13:36
Grünenthal Group
Duzallo®, a fixed-dose combination therapy for gout, approved in Europe
Aachen (ots) - Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo® marketing authorization for the EU/EEA. Duzallo® is a fixed-dose combination (FDC) therapy that combines allopurinol and lesinurad. It is indicated for the treatment of ...
28.08.2018 – 12:31
Syntellix AG
Syntellix's acquisition of 73% stake in materials specialist MSE results in strategically important vertical integration ahead of intended international flotation
Hannover (ots) - At yesterday's AGM, shareholders of Syntellix AG approved all the management's proposed resolutions by an overwhelming majority of 99%. - Preparations for the intended IPO will be supported by a multinational Supervisory Board comprising internationally renowned personalities from the world of ...
24.07.2018 – 12:00
Jennewein Biotechnologie GmbH
EIB provides funding to Jennewein
Rheinbreitbach (ots) - The European Investment Bank (EIB) provides new financing of EUR 15 million to Jennewein Biotechnologie GmbH, a highly innovative German company that offers a breakthrough technology for the production of rare functional sugars for a wide range of applications, including nutritional, pharmaceutical and cosmetic products. The Company is also a leading manufacturer of human milk oligosaccharides (HMOs), which form an essential part of human mother milk ...

12345678910Next